Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01309399 · ClinicalTrials.gov registry record · NA

Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur

A NA study of Osteoporosis, sponsored by Health Research.

Completed
Registry status
NA
Development phase
40
Enrollment target
1
Study location

NCT01309399: Completed NA study of Osteoporosis, sponsored by Health Research.

NCT01309399 is a NA study of Osteoporosis that has completed, run by Health Research. The registered enrollment target is 40 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01309399, a NA study of Osteoporosis, has completed, sponsored by Health Research.

COMPLETED
Registry status
NA
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

Teriparatide is a potent osteoporosis medication that helps prevent fractures, however, the investigators know little about its effect on the hip. The investigators will evaluate hip bone samples from patients treated with teriparatide before undergoing hip replacement. The information will help us understand how teriparatide might help reduce hip fracture risk.

Primary Outcome

At the time of surgery, the femoral neck and a small piece of bone will be obtained and measured for indices of bone formation in the femur and iliac crest in both placebo or teriparatide groups.

Conditions Studied

Osteoporosis

Interventions

  • OTHER placebo
  • DRUG Teriparatide

Study Locations (1)

New York

  • Helen Hayes Hospital - West Haverstraw

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2010-08
Est. Completion 2015-08
Phase NA
Health Research

1 total trials

What the finished NCT01309399 record still lists

NCT01309399 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT01309399 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01309399 about?

NCT01309399 is a clinical study titled "Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur". Teriparatide is a potent osteoporosis medication that helps prevent fractures, however, the investigators know little about its effect on the hip. The investigators will evaluate hip bone samples from patients treated with teriparatide before undergoing hip replacement. The information will help us ...

What is the current status of trial NCT01309399?

This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2010-08. Estimated completion is 2015-08.

What conditions does trial NCT01309399 study?

This clinical trial studies the following conditions: Osteoporosis.

What interventions are being tested in trial NCT01309399?

The interventions under investigation include: placebo (OTHER), Teriparatide (DRUG).

Who is sponsoring clinical trial NCT01309399?

This trial is sponsored by Health Research, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01309399 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Osteoporosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01309399's enrollment target sits among peer trials

40 62nd of 84 higher than 20 of 84 other Osteoporosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT01309399, the US trial registry maintained by the National Library of Medicine. NCT01309399 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.